About this trial
Modifications of cell surface markers (including EMMPRIN) were observed in conjunctival epithelial cells during dry eye syndrome ; this study aims to describe the modifications of the repartition of these cell surface markers before and after initiation of a treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years and over
Severe eye dryness (grade 3 or 4) as defined by the International Dry Eye Work Shop (2007): Frequent symptoms, Impregnation of fluorescein at the conjunctival level, marked fluorescein staining at the corneal level, Tear Break Up Time ≤ 5 seconds (fluorescein test) Schirmer's test score without anesthesia ≤ 5mm at 5 minutes
Patients without eye treatment or patients undergoing long-term stable eye treatment for whom a new treatment is being introduced
Disqualifiers
Known pregnancy or breastfeeding
Wearer of contact lenses
Topical ocular treatment
Known pregnancy or breastfeeding
Trial population
Patients with severe eye dryness will be compared with persons without eye dryness.
Trial design
Other
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
comparison of surface area of cell markers measured on conjunctival epithelial cells, in persons with and without severe eye dryness.
Comparison of the mean surface in patients before treatment for eye dryness versus in persons with no eye dryness. Immunofluorescence analysed in confocal microscopy on conjunctival impression cytology.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.